Monoclonal Antibody Detects Drug Resistance in Tumor Cells
Author Information
Author(s): S.P.C. Cole, S.A. Mohamdee, S.E.L. Mirski
Primary Institution: Queen's University
Hypothesis
The study investigates the development of a monoclonal antibody that recognizes a cell surface antigen associated with drug resistance in human ovarian carcinoma cells.
Conclusion
The monoclonal antibody MAb 7.4.1 recognizes a distinct antigen associated with drug resistance that is independent of P-glycoprotein.
Supporting Evidence
- MAb 7.4.1 labeled 84% of viable AD cells and only 1-2% of 9S cells, indicating its specificity.
- The antibody's reactivity was significantly reduced on formalin-fixed cells compared to unfixed cells.
- Immunoblotting showed that MAb 7.4.1 reacts with three proteins of estimated molecular weights of 186, 169, and 158 kDa.
Takeaway
Scientists created a special antibody that can find a part of cancer cells that helps them resist treatment, which is different from a known protein that usually does this.
Methodology
The study involved immunizing a mouse with drug-resistant ovarian cancer cells, fusing spleen cells with myeloma cells, and testing for specific antibodies using ELISA and flow cytometry.
Limitations
The antibody's reactivity was adversely affected by common fixatives, limiting its potential as an immunodiagnostic tool.
Participant Demographics
The study used a female Balb/c mouse for antibody production.
Want to read the original?
Access the complete publication on the publisher's website